• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Oncolytics Biotech Inc (NQ: ONCY )

    1.070 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 380,663
    Open 1.060
    Bid (Size) 1.010 (11)
    Ask (Size) 1.100 (26)
    Prev. Close 1.070
    Today's Range 1.010 - 1.080
    52wk Range 0.8401 - 1.750
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
    Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based... 
    Via FinancialNewsMedia

    Performance

    YTD
    -18.94%
    -18.94%
    1 Month
    -15.75%
    -15.75%
    3 Month
    +8.55%
    +8.55%
    6 Month
    -13.71%
    -13.71%
    1 Year
    -31.85%
    -31.85%

    More News

    Read More
    Extending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast Cancer
    Via News Direct
    Recap: Oncolytics Biotech Q4 Earnings
    Via Benzinga
    A Preview Of Oncolytics Biotech's Earnings
    Via Benzinga
    How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
    Via FinancialNewsMedia
    Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
    Via FinancialNewsMedia
    How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
    From FN Media Group LLC
    Via GlobeNewswire
    Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
    Via FinancialNewsMedia
    Topics Death
    Exposures Death
    Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
    Via FinancialNewsMedia
    Exposures Product Safety
    Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
    From FN Media Group LLC
    Via GlobeNewswire
    Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
    Via FinancialNewsMedia
    Topics Death
    Exposures Death
    Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
    From FN Media Group LLC
    Via GlobeNewswire
    Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
    Via FinancialNewsMedia
    Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
    From FN Media Group LLC
    Via GlobeNewswire
    ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024
    Via InvestorPlace
    Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
    Via FinancialNewsMedia
    Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
    Via FinancialNewsMedia
    Biotech Innovations Paving the Way in Breast Cancer Fight
    Via FinancialNewsMedia
    Topics Death
    Exposures Death Product Safety
    Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
    Via FinancialNewsMedia
    Exposures Product Safety
    Biotech’s Role in Addressing the Pancreatic Cancer Emergency
    Via FinancialNewsMedia
    ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023
    Via InvestorPlace
    Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
    Via FinancialNewsMedia
    Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
    Via Newsfile
    Earnings Scheduled For March 7, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.